Ahmed Harhash, MD
Cardiovascular Disease · Burlington, VTNPI 1083052252
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 42.0% of the total. Reporting peaked in 2019 at $3,310 and has fallen 91.1% since, to $294 in 2025.
Across 64 payments — averaging $100.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$2K
- Boston Scientific$945
- Edwards Lifesciences$491
- Abiomed$108
- Inari Medical, Inc.$93
- plus $191 from 6 others
Across 2 payments — averaging $41,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$83K
What the payments were for
- Travel & lodging$3,41153%
- Food & beverage$2,83844%
- Education$1723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 21 | $2,694 |
| Abbott | 19 | $1,899 |
| Boston Scientific | 6 | $945 |
| Edwards Lifesciences | 4 | $491 |
| Abiomed | 3 | $108 |
| Inari Medical, Inc. | 4 | $93 |
| Chiesi USA, Inc. | 1 | $70 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Bridgebio Pharma, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,421 in reported general payments places this provider in the 60th percentile of 27 cardiovascular disease providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 64 | $1,800,449 |
| VyndaqelTafamidis Meglumine | 28 | $577,265 |
| EntrestoSacubitril/Valsartan | 83 | $118,386 |
| JardianceEmpagliflozin | 96 | $113,109 |
| EliquisApixaban | 55 | $72,758 |
| XareltoRivaroxaban | 24 | $26,646 |
| OzempicSemaglutide | 24 | $24,701 |
| Torsemide | 53 | $1,327 |
| Eplerenone | 11 | $1,224 |
| Metoprolol Succinate | 78 | $1,026 |
| Spironolactone | 76 | $666 |
| Digoxin | 12 | $618 |
| Carvedilol | 41 | $614 |
| Atorvastatin Calcium | 42 | $501 |
| Pravastatin Sodium | 16 | $304 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Burlington
- Harold DauermanBurlington$248K
- Daniel LustgartenBurlington$171K
- Shubash AdhikariBurlington$59K
- Adipong BrickshawanaBurlington$37K
- Thomas GillilandBurlington$35K
- Benjamin IrvineBurlington$11K
- David SchneiderBurlington$7K
- Sharan SharmaBurlington$4K
- Trace BarrettBurlington$4K
- Sherrie KhadangaBurlington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.